142 related articles for article (PubMed ID: 23600973)
1. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Murtola TJ
Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
[No Abstract] [Full Text] [Related]
3. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Chen IJ
Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
[No Abstract] [Full Text] [Related]
4. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
6. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
[TBL] [Abstract][Full Text] [Related]
7. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
9. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
10. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
11. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
12. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
Huang J; He F; Huang M; Liu X; Xiong Y; Huang Y; Zhu L; Yang Y; Xu X; Yuan M
Eur J Med Chem; 2015; 96():83-91. PubMed ID: 25874333
[TBL] [Abstract][Full Text] [Related]
13. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
[TBL] [Abstract][Full Text] [Related]
14. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Gotoh A; Nagaya H; Kanno T; Nishizaki T
Pharmacology; 2012; 90(5-6):242-6. PubMed ID: 23007551
[TBL] [Abstract][Full Text] [Related]
15. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
16. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
18. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors.
Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T
Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884
[TBL] [Abstract][Full Text] [Related]
19. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
20. Drug Repositioning of the α
Florent R; Poulain L; N'Diaye M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
